Saitoh S, Sakata Y
Department of Gastroenterology, Aomori Prefectural Central Hospital, 2-1-1 Higashitsukurimichi, Aomori 030-8553, Japan.
Gan To Kagaku Ryoho. 2001 Oct;28(10):1345-51.
Irinotecan (CPT-11) is a potent inhibitor of topoisomerase I, and has demonstrated antitumor activity against metastatic colorectal cancer. In phase II studies, CPT-11 showed promising activity. Combining irinotecan with 5-fluorouracil (5-FU) and Leucovorin (LV) has shown benefits for patients with metastatic colorectal cancer CPT-11/5-FU/LV therapy is considered as a standard therapy. Weekly or biweekly administration of CPT-11 is most recommended.
伊立替康(CPT-11)是一种强效的拓扑异构酶I抑制剂,已显示出对转移性结直肠癌的抗肿瘤活性。在II期研究中,CPT-11表现出有前景的活性。将伊立替康与5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合使用已显示对转移性结直肠癌患者有益,CPT-11/5-FU/LV疗法被视为标准疗法。最推荐每周或每两周给药一次CPT-11。